UnknownNot Applicable

Modulation of Intestinal Barrier Function and Inflammation Via Butyrate-promoting Dietary Fibre

Sweden40 participantsStarted 2021-11-03

Plain-language summary

This study examines how a fermentable dietary fibre known to promote butyrate production impacts intestinal barrier function, intestinal microbiota, intestinal inflammation, and gastrointestinal symptoms in patients with microscopic colitis.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Signed informed consent
✓. Diagnosis of microscopic colitis (collagenous or lymphocytic colitis)
✓. Active disease with no medication (e.g. budesonide) or stable budesonide treatment with or without symptoms
✓. Age between 18-75

Exclusion criteria

✕. Previous diagnosis of other organic gastrointestinal disease that interferes with the outcome parameters used in this study (e.g. ulcerative colitis)
✕. Previous abdominal surgery which might influence gastrointestinal function, except appendectomy and cholecystectomy
✕. History of or present gastrointestinal malignancy or polyposis
✕. Diagnosis of gastrointestinal infection within the last 6 months
✕. Current diagnosis of dementia, severe depression, major psychiatric disorder, or other incapacity for adequate cooperation
✕. Chronic neurological/neurodegenerative disease (e.g. Parkinson's disease)
✕. Autoimmune disease (e.g. rheumatoid arthritis)
✕. Chronic pain syndromes (e.g. fibromyalgia)

What they're measuring

Colonic permeability in vivo

Timeframe: 6 weeks

Trial details

NCT IDNCT05058131

SponsorÖrebro University, Sweden

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-12-30

Contact for this trial

Richard A Forsgård, PhD

0790614037 richard.forsgard@oru.se

View on ClinicalTrials.gov More Microscopic Colitis trials